Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc)(Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc))

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

Measles mumps and rubella virus vaccine、Measles, Mumps and Rubella Vaccine, Live、Measles, Mumps and Rubella Virus Vaccine Live

+ [4]

靶点-

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GlaxoSmithKline LLCGlaxoSmithKline GmbH & Co. KG

非在研机构

GSK Plc

最高研发阶段批准上市

首次获批日期

德国 (1998-05-31)

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

25

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床试验

CTRI/2024/11/077318

/ Not yet recruiting临床4期

A phase IV, double blind, randomized, active control clinical studycomparing safety and immunogenicity of SII-Measles-Mumps-Rubella vaccine with PRIORIX (GSK) in healthy infants in India - MMR01/23

开始日期2024-12-10

申办/合作机构

Serum Institute of India Pvt Ltd.

TCTR20231108008

/ Not yet recruiting临床4期

A Phase IV, Non-Inferiority, Double Blind, Randomized Controlled Clinical Trial comparing Safety and Immunogenicity of SII-Measles-Mumps-Rubella vaccine with Priorix (GSK) in healthy infants

开始日期2024-01-01

申办/合作机构-

CTIS2023-503845-79-01

/ Not yet recruiting临床2期IIT

The induction of respiratory immune responses by epicutaneous vaccinationwith the MMR vaccine - LGS.MMR.02.2022.2025

开始日期2023-06-20

申办/合作机构

Rigshospitalet

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

2,424

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2025-02-01·JOURNAL OF INFECTION

Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden

Article

作者: Lahdenkari, Mika ; Nieminen, Heta ; Benn, Christine Stabell ; Gehrt, Lise ; Palmu, Arto A ; Feiring, Berit ; Laake, Ida ; Trogstad, Lill ; Englund, Hélène ; Möller, Sören ; Sørup, Signe

OBJECTIVES:

To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations.

METHODS:

Register based cohort study following 1,397,027 children born in Denmark, Finland, Norway, and Sweden until 2 years of age. Rates of infectious disease hospitalisations with minimum one overnight stay according to time-varying vaccination status were compared using Cox proportional hazards regression analysis with age as the underlying timescale and including multiple covariates. Summary estimates were calculated using random-effects meta-analysis.

RESULTS:

Compared with DTaP3 and no MMR vaccine, MMR after DTaP3 was associated with reduced rates of infectious disease hospitalisations: aHR was 0.86 (0.83-0.89) in Denmark, 0.70 (0.64-0.75) in Finland, 0.71 (0.68-0.74) in Norway, and 0.71 (0.65-0.77) in Sweden: summary estimate was 0.75 (0.65 to 0.84). A beneficial association was also seen in a negative control exposure analysis (3 vs. 2 DTaP doses): summary estimate aHR was 0.81 (0.75-0.87).

CONCLUSIONS:

Having MMR as the most recent vaccine was consistently associated with reduced rates of infectious disease hospitalisation. However, bias may account for at least some of the observed association. Randomised controlled trials are warranted to inform the optimal timing of MMR for both its specific and potential non-specific effects.

2025-02-01·AMERICAN JOURNAL OF HEMATOLOGY

Treatment‐Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort

Article

作者: Narula, Gaurav ; Shetty, Dhanlaxmi ; Tembhare, Prashant ; Banavali, Shripad ; Agiwale, Jayesh ; Rajpal, Sweta ; Subramanian, Papagudi G. ; Dhamne, Chetan ; Roy Moulik, Nirmalya ; Srinivasan, Shyam ; Patkar, Nikhil ; Chichra, Akanksha ; Mohanty, Purvi ; Chatterjee, Gaurav ; Rane, Pallavi ; Jain, Hemani ; Keerthivasagam, Swaminathan

ABSTRACT:

Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%–3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long‐term effects on growth and bone health in children. We prospectively studied treatment‐free remission (TFR) in 45 children with pCML in chronic phase on imatinib. Eligibility criteria were as per current NCCN guidelines, with a less stringent qPCR monitoring scheduled every 3 months. TFR was successful in 71.1% (32 out of 45) of patients after a median follow‐up of 25 (range: 6–42) months. The TFR rates at 12 and 24 months were 70% and 66%, respectively. Children under 5 years had a TFR rate of 88.9%, compared to 61.8% in those over 5 years (p = 0.18). Eleven of the 13 patients who lost MMR did so within 6 months of discontinuation. The cumulative incidence of loss in MMR at 6, 12, and 24 months was 26.4%, 27%, and 33%, respectively. Ten out of 13 (76.9%) patients with discontinuation failure (DF) regained MMR within 3 (2–20) months of restarting imatinib. A significant correlation was found between higher T‐regulatory cell levels at baseline and DF (p = 0.005). More than half patients showed improved bone mineral density after 2 years of TFR. Our findings suggest that high TFR rates can be attained in pCML, with added benefits for bone health. Less frequent molecular monitoring was not associated with adverse outcomes and there seems to be a role of the immune system in sustaining TFR. The study is registered in the Clinical Trials Registry‐India (CTRI/2020/11/029199).

2025-01-01·PUBLIC HEALTH REPORTS

Cost-Effectiveness Analysis of Routine Outreach and Catch-Up Campaign Strategies for Measles, Mumps, and Rubella Vaccination in Chuuk, Federated States of Micronesia

Article

作者: Tippins, Ashley ; Leidner, Andrew J. ; Meghani, Mehreen ; Pike, Jamison

Objective::

The Federated States of Micronesia (FSM) experience periodic outbreaks of vaccine-preventable diseases. Our objective was to assess the cost-effectiveness of routine outreach and catch-up campaign strategies for increasing vaccination coverage for the measles, mumps, and rubella (MMR) vaccine among children aged 12 months through 6 years in Chuuk, FSM.

Methods::

We used a cost-effectiveness model to assess 4 MMR vaccination strategies from a public health perspective: routine outreach conducted 4 times per year (quarterly routine outreach), routine outreach conducted 2 times per year (biannual routine outreach), catch-up campaigns conducted once per year (annual catch-up campaign), and catch-up campaigns conducted every 2 years with quarterly routine outreach in non–catch-up campaign years (status quo). We calculated costs and outcomes during a 5-year model horizon and summarized results as incremental cost-effectiveness ratios. We analyzed the following public health outcomes: additional protected person-month (PPM), doses administered and protected people (ie, a child who completed a 2-dose MMR series). We conducted 1-way sensitivity analyses to evaluate the stability of incremental cost-effectiveness ratios and to identify influential model inputs.

Results::

Among the 4 MMR vaccination strategies, quarterly routine outreach was the most effective and most expensive strategy, and biannual routine outreach was the least expensive and least effective strategy. Quarterly routine outreach (vs status quo) yielded approximately an additional 7001 PPMs and 132 vaccine doses administered, with incremental costs of about $4 per PPM, $193 per dose administered, and $123 per protected person.

Conclusion::

Routine outreach and catch-up campaign vaccination strategies can be important interventions to improve health in Chuuk, FSM. More frequent routine outreach events could improve MMR coverage and reduce the likelihood of outbreaks of vaccine-preventable diseases such as measles and mumps.

15

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的新闻（医药）

2024-12-02

·Endpoints

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Former FDA Commissioner Scott Gottlieb opposed President-elect Donald Trump’s choice to lead the Department of Health and Human Services, saying Robert F. Kennedy Jr.’s policies would lead to a resurgence of preventable diseases and cost lives. Gottlieb led the FDA in the first Trump administration. In comments on CNBC Friday, he called Kennedy (widely known as RFK Jr.) a “committed” anti-vaccine advocate who, if confirmed by the Senate, could easily take steps to decrease the use of vaccines in the US. “I have deep concerns about Kennedy’s stated intentions to roll back core public health protections, particularly as it relates to childhood vaccines,” Gottlieb said. “I think if RFK follows through on his intentions, and I believe he will and I believe he can, it will cost lives in this country.” He said he had raised his objections with Republican senators who will vote on the selection of Kennedy, who Trump announced last month . Trump’s pick of Kennedy has been followed by a series of announcements that would put skeptics of longstanding US healthcare and public health policy in positions of power. Along with Kennedy, that includes Trump’s choice to lead the National Institutes of Health (Stanford researcher and Covid policy skeptic Jay Bhattacharya) and the CDC (former congressman Dave Weldon). While in Congress, Weldon pushed for significant changes to vaccine policy that have been sought by vaccine skeptics. Kennedy has questioned the use of childhood vaccines for years, attempting to link them to the rise of autism and raising other questions about their safety. While his remarks on his exact plans have shifted over time, at their core is the idea that he wants to push away from a policy of vaccine requirements — meant to create widespread immunity and protect those who can’t be vaccinated or who have immune issues — and create a policy of individual choice. “I’m not going to take away anybody’s vaccines,” Kennedy said in a television interview last month. “People can make individual assessments about whether that product is good for them.” The Trump transition team didn’t immediately respond to a request for comment. Gottlieb in particular warned about a resurgence of measles, a highly infectious disease that can be deadly in young children. Vaccination rates of the measles, mumps and rubella (MMR) vaccine have fallen in some parts of the country, and been followed by occasional outbreaks. Nationally, kindergarten vaccination rates are around 92% with two doses of MMR vaccine, according to a CDC study published this year . But in some states, they are far lower. In Idaho, only about 80% of children have received the vaccine. In Wisconsin, the rate is 85%. Those rates are below the 95% target the CDC says is a benchmark for creating population-level immunity to the disease. “If we lose another 5%, we’re going to see a situation where we see distributed outbreaks,” Gottlieb said. “What I worry about is that we’re at a tipping point where we’re going to see epidemics of diseases that have long been vanquished.”

疫苗

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-12

·生物制品圈

2024年美国免疫实践咨询委员会≥19岁成人疫苗推荐免疫程序

2023年10月，美国免疫实践咨询委员会（ACIP）批准了2024年美国≥19岁成人疫苗推荐免疫程序。该程序每年发布一次，以整合和总结ACIP关于成人疫苗接种建议的更新，并协助医疗保健提供者实施当前的ACIP建议。ACIP关于每种疫苗使用的建议是在对疫苗相关数据进行深入分析后制定，这些数据包括疾病流行病学和社会影响、疫苗效力和有效性、疫苗安全性、证据质量、项目实施的可行性、对健康公平的影响以及免疫政策的经济分析。概述012024年≥19岁成人疫苗推荐免疫程序中针对特定疫苗的变化包括对呼吸道合胞病毒疫苗（RSV）、流感疫苗、COVID-19疫苗、灭活脊髓灰质炎病毒疫苗（IPV）、猴痘疫苗（Mpox）和脑膜炎球菌A、B、C、W、Y血清群五价疫苗（MenACWY- TT/MenB-FHbp）。其他变化包括说明了甲型肝炎疫苗（HepA）、乙型肝炎疫苗（HepB）、人乳头瘤病毒疫苗（HPV）、麻疹、腮腺炎和风疹联合疫苗（MMR）、肺炎球菌疫苗以及破伤风、白喉和百日咳疫苗（Tdap）的建议。01表1.成人免疫程序推荐的疫苗疫苗缩写商品名称新冠疫苗1vCOV-mRNAComirnaty®/辉瑞-BioNTech新冠肺炎疫苗Spikevax®/莫德纳新冠肺炎疫苗1vCOV-aPSNovavax新冠疫苗b型流感嗜血杆菌疫苗HibActHIB®Hiberix®PedvaxHIB®甲型肝炎疫苗HepAHavrix®Vaqt®甲型肝炎和乙型肝炎疫苗HepA-HepBTwinrix®乙型肝炎疫苗HepBEngerix-B®Heplisav-B®PreHevbrio®Recombivax HB®人乳头瘤病毒疫苗HPVGardasil 9®流感疫苗（灭活）IIV4众多品牌流感疫苗（活疫苗、减毒疫苗）LAIV4FluMist® Quadrivalent流感疫苗（重组）RIV4Flublok® Quadrivalent麻疹、腮腺炎和风疹疫苗MMRM-M-R II®Priorix®脑膜炎球菌A、C、W、Y血清群疫苗MenACWY-CRM MenACWY-TTMenveo®MenQuadfi®B血清群脑膜炎球菌疫苗MenB-4CMenB-FHbpBexsero®Trumenba®A、B、C、W、Y血清群脑膜炎球菌疫苗MenACWY-TT/MenB-FHbpPenbraya™猴痘疫苗MpoxJynneos®肺炎球菌结合疫苗PCV15PCV20Vaxneuvance™Prevnar 20™肺炎球菌多糖疫苗PPSV23Pneumovax 23®脊髓灰质炎病毒疫苗IPVIpol®呼吸道合胞病毒疫苗RSVArexvy®Abrysvo™破伤风和白喉类毒素疫苗TdTenivac®Tdvax™破伤风白喉类毒素和无细胞百日咳疫苗TdapAdacel®Boostrix®水痘疫苗VARVarivax®重组带状疱疹疫苗RZVShingrix02表2.2024年美国按年龄组分列的推荐成人免疫接种时间表03 表3.按医疗状况或其他迹象分列的推荐成人免疫接种时间表，美国，2024年疫苗说明02• 新的“附加信息”部分现在增加了2024年成人免疫计划的注释部分。• COVID-19：现在建议所有成年人至少接种1剂更新的（2023-2024年组分）COVID-19疫苗。所需的剂次数和剂次间隔可能因患者既往疫苗接种史、免疫功能低下状态和使用的疫苗产品而异。此外，COVID-19说明部分分为“常规疫苗接种”部分和“特殊情况”部分，前者描述了针对普通人群的疫苗接种建议，后者描述了针对中度或重度免疫功能低下人群的疫苗接种建议。• HepA：为了更好地与ACIP政策保持一致，“常规疫苗接种”部分的项目符号被修改为“任何未完全接种疫苗并要求接种疫苗的人”。• HepB：在“常规疫苗接种”部分，在描述针对≥60岁人群的基于风险的疫苗接种建议的项目符号中添加了额外的背景和细节。此外，在“常规疫苗接种”部分的末尾增加了一个注释，描述了对≥60岁糖尿病患者的共同临床决策建议。• HPV：在“常规疫苗接种”部分，删除了关于未按免疫程序完成接种的指南。当使用推荐的接种间隔完成全程HPV疫苗接种后，不建议额外剂次。• 流感：在“特殊情况”部分，删除了所有讨论鸡蛋过敏史的部分，并在“特殊情况”部分的末尾添加了一个注释，说明有鸡蛋过敏史的人可以接种任何适宜的流感疫苗。最后，删除了描述吉兰-巴雷综合征的部分。• MMR：对“常规疫苗接种”部分进行了细微更改，以提高语言清晰度。• 脑膜炎球菌：添加了资源链接，以帮助医疗保健提供者共享MenB疫苗接种的临床决策建议。有关使用新许可的五价脑膜炎球菌疫苗（Penbraya）的信息在脑膜炎球菌注释部分的末尾提供。• 猴痘：猴痘疫苗接种是成人疫苗推荐免疫程序注释部分的新内容。列出了需要常规接种Jynneos疫苗的危险因素。有关在医疗保健提供者和孕妇中使用Jynneos的要点在Mpox注释部分的末尾提供。• 肺炎球菌：在“常规疫苗接种”和“特殊情况”部分进行了细微编辑，以明确肺炎球菌疫苗的指导和最低间隔。• 脊髓灰质炎病毒：在“常规疫苗接种”部分添加了其他背景信息。本节现在呼吁未接种疫苗或未完全接种疫苗的成年人完成3剂IPV基础免疫。增加了一份声明，指出大多数在美国出生和长大的成年人可以假设他们小时候接种了脊髓灰质炎疫苗。“特殊情况”部分介绍了对已完成三剂基础免疫接种且暴露于脊髓灰质炎病毒风险增加的成年人进行一次性、终生灭活脊灰疫苗加强剂。• 呼吸道合胞病毒：今年增加了一个新的呼吸道合胞病毒注释部分。该部分以“常规疫苗接种”部分开始，描述了美国大陆大部分地区在9月至1月妊娠32-36周期间孕妇中使用Abrysvo（辉瑞公司）的情况。此外，还指出建议母亲接种RSV疫苗或婴儿接种Nirsevimab（RSV单克隆抗体）以预防婴儿呼吸道合胞病毒下呼吸道感染。在RSV注释部分的末尾添加了一条注释，以承认某些司法管辖区的RSV季节性可能与美国大陆大部分地区不同，并且提供者应遵循公共卫生当局关于孕产妇RSV疫苗接种时间的指导，基于当地的RSV季节性。 “特殊情况”部分描述了≥60岁人群接种疫苗的共同临床决策建议;可以使用Abrysvo（辉瑞公司）或Arexvy（GSK）。此外，还添加了一个资源链接，以帮助医疗保健提供者共享RSV疫苗接种的临床决策建议。最后，增加了一个注释，列出了医疗保健提供者在考虑患者患严重RSV疾病的风险以及疫苗接种的潜在益处时应考虑的风险因素和医疗条件。• Tdap：在Tdap部分的末尾添加了一个注释，以说明在10岁时接种Tdap疫苗可算作11-12岁时常规推荐的青少年剂次。参考文献：Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:11–15. DOI：http://dx.doi.org/10.15585/mmwr.mm7301a3识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床研究

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	美国	GlaxoSmithKline LLC	2022-06-03
腮腺炎	美国	GlaxoSmithKline LLC	2022-06-03
风疹	美国	GlaxoSmithKline LLC	2022-06-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
嗜血杆菌感染	临床3期	澳大利亚	GSK Plc	2006-06-01
脑膜炎	临床3期	澳大利亚	GSK Plc	2006-06-01
水痘	临床3期	美国	GSK Plc	2003-10-06
甲型肝炎	临床3期	美国	GSK Plc	2003-10-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00226499 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	5,803	Priorix-tetra™ (MMRV Group)	顧膚夢網顧壓窪鬱鹹構(窪壓衊廠遞願積鏇鑰製) = 鬱繭齋襯膚廠網夢範鹽構積鏇鏇獵鏇構蓋獵窪 (鹽網餘築顧餘憲築糧製, 艱艱積淵襯醖選壓淵糧 ~ 窪鏇鏇齋餘憲簾壓齋蓋) 更多	-	2019-09-23
				Varilrix™+Priorix™ (OKAH Group)	顧膚夢網顧壓窪鬱鹹構(窪壓衊廠遞願積鏇鑰製) = 選觸鬱齋餘獵蓋顧範餘構積鏇鏇獵鏇構蓋獵窪 (鹽網餘築顧餘憲築糧製, 鏇糧糧選鏇憲鬱壓衊積 ~ 鬱膚艱蓋構艱淵淵遞範) 更多
NCT01681992 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,538	Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Min Group)	艱繭鬱憲衊鑰遞構醖窪(鹽淵願鏇餘窪顧壓選鹽) = 窪築繭艱蓋獵鹽積齋選憲廠餘鬱願糧糧築夢夢 (艱選構窪築積顧構範夢, 鹹膚糧鹽衊蓋壓壓範廠 ~ 積築鑰鬱鹽艱糧齋鹹鏇) 更多	-	2018-08-17
				Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Med Group)	艱繭鬱憲衊鑰遞構醖窪(鹽淵願鏇餘窪顧壓選鹽) = 積簾窪積獵餘觸醖鑰鬱憲廠餘鬱願糧糧築夢夢 (艱選構窪築積顧構範夢, 網築積壓構獵蓋遞鹹製 ~ 鏇糧壓遞餘鬱醖廠鏇壓) 更多
NCT00969436 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹 ... 更多	450	GSK Biological's investigational MMRV vaccine 208136 (Priorix-Tetra Group)	顧範窪鹹壓繭膚範繭鹽(壓鹹壓餘衊窪糧鬱鹽鬱) = 憲廠膚構襯範遞夢窪製憲廠鏇鑰範繭繭蓋淵顧 (醖壓齋齋蓋夢獵齋選構, 壓獵醖築積膚艱網鬱廠 ~ 夢獵鏇膚齋艱齋製範選) 更多	-	2017-09-25
				GSK Biological's investigational MMRV vaccine 208136+Priorix™ (Priorix/ Priorix-Tetra Group)	顧範窪鹹壓繭膚範繭鹽(壓鹹壓餘衊窪糧鬱鹽鬱) = 遞鬱鹹鬱衊簾餘廠鹽憲憲廠鏇鑰範繭繭蓋淵顧 (醖壓齋齋蓋夢獵齋選構, 網鹹鬱選鹽鹽遞遞鑰選 ~ 範壓築鏇鬱窪醖願夢衊) 更多
NCT01621802 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	4,011	ProQuad+Kinrix+M-M-R II (Com_MMR_CO Group)	繭廠繭製醖鹹膚壓網鏇(積蓋範淵廠膚鏇壓鏇糧) = 繭構憲構鏇遞襯壓願鏇範願夢鏇壓蓋獵積糧範 (膚構積餘顧鹽夢獵獵壓, 憲築顧繭獵夢襯範蓋獵 ~ 鑰膚鬱範鬱獵簾憲廠製) 更多	-	2017-09-13
				Priorix (Inv_MMR_I Group)	繭廠繭製醖鹹膚壓網鏇(積蓋範淵廠膚鏇壓鏇糧) = 鑰鹹膚繭夢壓醖選築鹽範願夢鏇壓蓋獵積糧範 (膚構積餘顧鹽夢獵獵壓, 選選簾淵鹹遞觸齋製鬱 ~ 壓衊醖構獵築繭壓醖餘) 更多
NCT02058563 (CTgov)	临床3期	风疹 \| 腮腺炎 \| 麻疹	996	Priorix® (INV_MMR Group)	構鑰鹽簾願顧壓膚簾蓋(鏇淵鏇廠襯選選顧膚鏇) = 醖壓鏇築衊淵淵鹹窪餘顧衊範構製齋範鏇餘糧 (齋餘鹽簾鬱顧顧鏇顧範, 願鬱觸艱範觸淵醖蓋願 ~ 鹹獵鏇廠願選鏇齋艱淵) 更多	-	2017-04-10
				Merck's M-M-R®II, Measles, Mumps, (COM_MMR Group)	構鑰鹽簾願顧壓膚簾蓋(鏇淵鏇廠襯選選顧膚鏇) = 遞築鹹願築觸鹹簾夢鹹顧衊範構製齋範鏇餘糧 (齋餘鹽簾鬱顧顧鏇顧範, 鹹積構衊繭鹽鹹鬱製襯 ~ 膚淵淵鹽範築齋鑰鹽選) 更多
NCT00381615 (CTgov)	临床2期	-	147	rMenB+DTaP-Hib-IPV+MenC-Hib+MMR+PC7 (rMenB)	鹹醖醖鏇壓獵遞鹽蓋鹹(淵餘鏇製壓繭窪鹹積鹹) = 繭鑰衊網鑰選壓築製選選廠壓鏇襯繭窪鹽觸鹹 (鏇衊願夢衊艱憲廠糧鹹, 夢齋鹹顧糧齋廠夢鹽選 ~ 淵餘醖憲鏇鏇繭淵顧鑰) 更多	-	2015-10-09
				DTaP-Hib-IPV+rMenB+OMV+MenC-Hib+MMR+PC7 (rMenB+OMV)	鹹醖醖鏇壓獵遞鹽蓋鹹(淵餘鏇製壓繭窪鹹積鹹) = 繭淵構齋鏇簾廠簾積齋選廠壓鏇襯繭窪鹽觸鹹 (鏇衊願夢衊艱憲廠糧鹹, 鹹壓築襯糧夢壓糧顧窪 ~ 餘衊艱鏇鏇廠選蓋鏇遞) 更多
NCT00134719 (CTgov)	临床2期	脑膜炎 \| 嗜血杆菌感染	1,104	MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta (MenHibrix Group)	鏇醖艱選積獵遞觸積膚(襯醖膚鏇廠餘膚窪網鹽) = 襯夢窪艱蓋選築鏇網積築繭艱夢齋醖廠廠夢觸 (顧選淵願願鹽構積構積, 繭獵鏇選鏇鬱憲製觸鹹 ~ 獵鹽網憲廠鬱簾鑰積膚) 更多	-	2012-07-20
				ActHIB®+MenHibrix (Hib-MenCY-TT)+M-M-R®II+Varivax®+Prevenar®+Infanrix® Penta+Meningitec® (ActHIB + Meningitec Group)	觸範範膚餘憲齋壓繭範(網艱膚廠憲鹹鏇製衊鬱) = 鏇鏇糧鏇糧餘壓選鏇衊繭網醖膚窪蓋淵襯積鏇 (網廠糧鑰繭積遞選襯鹽, 簾膚醖積鏇獵淵餘構廠 ~ 窪鹽鑰願壓醖鹹夢鬱鏇) 更多
NCT00861744 (CTgov)	临床2期	甲型肝炎 \| 风疹 \| 腮腺炎 ... 更多	1,259	GSK Biological's investigational vaccine 209762+Varivax®+Havrix®+Prevnar® (Priorix 1 Group)	餘選鹹餘廠醖憲鏇選範(糧網鏇艱膚鹽遞壓鑰遞) = 齋選醖選鬱糧膚遞鹹醖簾醖鹹壓夢顧窪積醖憲 (糧膚壓壓餘鹹膚積鹽遞, 製積製襯鑰鹽淵製築選 ~ 顧鹹壓蓋觸艱鏇淵餘積) 更多	-	2011-11-04
				GSK Biological's investigational vaccine 209762+Varivax®+Havrix®+Prevnar® (Priorix 2 Group)	餘選鹹餘廠醖憲鏇選範(糧網鏇艱膚鹽遞壓鑰遞) = 網蓋餘築鬱廠觸鏇齋鏇簾醖鹹壓夢顧窪積醖憲 (糧膚壓壓餘鹹膚積鹽遞, 廠簾鹽夢壓繭構鑰鑰齋 ~ 鏇淵遞鏇夢構獵淵憲醖) 更多
NCT00197015 (CTgov)	临床3期	甲型肝炎 \| 风疹 \| 腮腺炎 ... 更多	1,474	Havrix® (HAV Group)	餘選鹽觸壓鑰獵窪鹽鹹(壓鑰憲構遞鏇願廠齋鑰) = 憲窪齋廠衊製淵獵淵製醖顧鹽窪觸積願鏇鑰醖 (襯鹹艱壓膚艱獵鏇糧蓋, 遞範鏇衊餘夢鏇繭壓築 ~ 窪壓鹽夢範製鑰鬱鑰糧) 更多	-	2010-04-01
				M-M-R®II+VARIVAX®+Havrix® (MMR+V→HAV Group)	淵網繭廠糧襯鹹構衊衊(鹹憲襯願網醖範積鏇範) = 壓壓網製積糧範壓構鏇鹹憲壓鏇淵醖鑰鹽築窪 (糧選製獵觸衊簾夢餘鬱, 蓋窪積構鬱繭繭繭襯憲 ~ 獵鏇襯繭網壓壓選憲餘) 更多
NCT00326118 (CTgov)	临床3期	脑膜炎 \| 嗜血杆菌感染	433	Priorix™+Haemophilus influenzae type b (Menitorix Group)	製築鹽獵餘餘觸餘積鏇(廠壓膚鑰膚蓋廠憲範積) = 艱觸願遞廠鏇願夢築淵積鏇簾製糧簾鹹壓觸膚 (範蓋獵簾艱築鑰願壓蓋, 鹽選築網簾糧鏇壓積壓 ~ 鹽遞範鹽鬱製窪糧襯廠) 更多	-	2009-10-23
				Hiberix™+Priorix™+Meningitec™ (Meningitec + Hiberix Group)	製築鹽獵餘餘觸餘積鏇(廠壓膚鑰膚蓋廠憲範積) = 壓獵糧齋選壓選顧膚製積鏇簾製糧簾鹹壓觸膚 (範蓋獵簾艱築鑰願壓蓋, 淵顧顧製醖窪鏇齋簾艱 ~ 構膚簾範製鬱壓衊鹽鹹) 更多